WO2021213502A1 - 包含稀有人参皂苷Rg6和F4的改善睡眠药物组合物 - Google Patents
包含稀有人参皂苷Rg6和F4的改善睡眠药物组合物 Download PDFInfo
- Publication number
- WO2021213502A1 WO2021213502A1 PCT/CN2021/089324 CN2021089324W WO2021213502A1 WO 2021213502 A1 WO2021213502 A1 WO 2021213502A1 CN 2021089324 W CN2021089324 W CN 2021089324W WO 2021213502 A1 WO2021213502 A1 WO 2021213502A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ginsenoside
- pharmaceutical composition
- sleep
- weight
- parts
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Definitions
- the present invention relates to the field of biomedicine, in particular to a rare ginsenoside Rg6/F4 composition with synergistic activity and sleep-aiding activity.
- the drugs used for the treatment of sleep disorders on the market mainly include chemical drugs such as barbiturates, benzodiazepines, and zodiazetan. Most of these drugs can shorten the time to fall asleep, prolong sleep time and improve the quality of sleep, but they will cause harm to the body after taking them. A series of toxic and side effects, such as drowsiness, fatigue, loss of appetite, memory loss, intestinal discomfort, and severe drug tolerance after taking it. Although in the 1990s, it was found that melatonin 20mg/d orally is effective Improve the chronic insomnia caused by non-circadian rhythm disorders and develop corresponding drugs and health products, but the effect is not very satisfactory. As of October 2018, a total of 16,690 domestic health foods have been approved, of which only 2.8% of them improve sleep. Therefore, the development of sleep-improving products that are effective and beneficial to the human body is an important task for market and social development.
- chemical drugs such as barbiturates, benzodiazepines, and zodiazetan.
- Most of these drugs can shorten
- Ginseng, American ginseng and Panax notoginseng are all traditional Chinese medicinal materials in China.
- the active ingredients ginsenosides Rb1, Rd, Rg1, etc. have been reported to improve immunity, reduce inflammation, improve sleep and other effects, and have no dependence and withdrawal reactions.
- Ginsenosides Rg6 and F4 are produced by the triol saponins Rg1, Re deglycosylated and dehydrated. Currently, they are mainly used in the treatment of non-small cell lung cancer, anti-thrombosis, treatment of cerebral infarction, central retinal vein occlusion and other diseases, improving sleep and improving There is no report on sleep quality.
- the purpose of the present invention is to provide a pharmaceutical composition for improving sleep with ginsenoside Rg6 and/or F4 as active ingredients.
- Ginsenoside Rg6 can increase the 5-HTP content in brain tissue. , Improve the slow wave sleep of animals. Moreover, when ginsenosides Rg6 and F4 are used in combination in a specific ratio, the effect of improving sleep is better than that of ginsenosides Rg1 and Rb1, which have been reported to improve sleep, and also better than the effect of Rg6 and F4 when acting alone. This may be due to the combination
- the substance can simultaneously increase the levels of GABA and 5-HTP in animal brain tissues, and synergistically play a role in improving sleep.
- the present invention includes:
- a pharmaceutical composition that can be used to improve sleep comprising as active ingredients effective amounts of ginsenoside Rg6 and ginsenoside F4 for improving sleep, and a pharmaceutically acceptable carrier.
- the ginsenoside Rg6 The weight ratio of ginsenoside F4 to ginsenoside F4 is 1:1 to 3:1.
- the weight ratio of ginsenoside Rg6 and ginsenoside F4 is 2:1.
- the pharmaceutical composition according to item 1 based on 100 parts by weight of total ginsenosides contained in the pharmaceutical composition, the total of ginsenoside Rg6 and ginsenoside F4 contained in the pharmaceutical composition is 100 parts by weight .
- ginsenoside Rg6 and ginsenoside F4 in preparing a pharmaceutical composition for improving sleep, wherein, in the pharmaceutical composition, the weight ratio of ginsenoside Rg6 and ginsenoside F4 is 1:1-3: 1.
- ginsenoside F4 can inhibit neuronal excitement by regulating the levels of ⁇ -aminobutyric acid (GABA) and Glu, and exhibit a calming and tranquilizing effect, thereby improving sleep; while ginsenoside Rg6 can increase The content of 5-HTP in brain tissue can improve the slow wave sleep of animals.
- GABA ⁇ -aminobutyric acid
- ginsenoside Rg6 can increase The content of 5-HTP in brain tissue can improve the slow wave sleep of animals.
- the ginsenoside Rg6 contained in the pharmaceutical composition is 5 parts by weight or more, preferably 10 parts by weight Parts by weight or more, more preferably 20 parts by weight or more, more preferably 50 parts by weight or more, more preferably 70 parts by weight or more, more preferably 80 parts by weight or more, more preferably 90 parts by weight or more, more preferably 95 parts by weight or more, more preferably 99 parts by weight Above, more preferably 100 parts by weight.
- ginsenoside F4 in the preparation of a pharmaceutical composition for improving sleep.
- the ginsenoside F4 contained in the pharmaceutical composition is 5 parts by weight or more, preferably 10 parts by weight Parts by weight or more, more preferably 20 parts by weight or more, more preferably 50 parts by weight or more, more preferably 70 parts by weight or more, more preferably 80 parts by weight or more, more preferably 90 parts by weight or more, more preferably 95 parts by weight or more, more preferably 99 parts by weight Above, more preferably 100 parts by weight.
- the above-mentioned pharmaceutical composition may also contain vitamins and/or trace elements (for example, iron) for tranquilizing and invigorating qi.
- vitamins and/or trace elements for example, iron
- the above-mentioned pharmaceutical composition may contain 0.1-0.8 parts by weight of vitamins and/or 0.01-0.1 parts by weight of trace element iron.
- the above-mentioned pharmaceutical composition may be, for example, an oral agent or an injection.
- the oral agent may be, for example, a hard capsule, a soft capsule, a sustained-release capsule, a sugar-coated tablet, a powder, a granule, a tablet, a granule, a dripping pill, a honey pill, a syrup or an oral liquid; the injection is a solution type, mixed Suspension type, emulsion type or lyophilized powder.
- the above-mentioned pharmaceutical composition may also be an external dosage form, such as an ointment, gel, spray or patch.
- the above-mentioned pharmaceutical composition may contain excipients or other pharmaceutically acceptable carriers.
- the ratio of the auxiliary material to the active ingredient of the medicine may be, for example, the active ingredient accounts for 30% to 50% by weight, and the auxiliary material accounts for 70% to 50% by weight.
- the auxiliary material can be, for example, one or more of sodium hyaluronate, magnesium stearate, sodium alginate, starch, microcrystalline cellulose, chitosan, stachyose, binder or collagen.
- the present invention provides a pharmaceutical composition that can be used to improve sleep, which comprises as active ingredients, ginsenoside Rg6 and ginsenoside F4 in effective amounts for improving sleep, and a pharmaceutically acceptable carrier,
- the weight ratio of the ginsenoside Rg6 and the ginsenoside F4 is 1:1 to 3:1.
- ginsenoside Rg6 refers to the compound described in Chemical Formula 1 below.
- ginsenoside Rg6 is a known compound and can be prepared by methods known in the art. For example, using ginsenoside Rb1 or Rd as a raw material, through targeted catalytic conversion, ginsenoside Rg6 with a purity of more than 98% can be obtained.
- ginsenoside F4 refers to the compound described in the following chemical formula 2.
- ginsenoside F4 is a known compound and can be prepared by methods known in the art. Using ginsenoside Rb1 or Rd as raw materials, through targeted catalytic conversion, ginsenoside F4 with a purity of more than 98% can be obtained.
- the pharmaceutical composition of the present invention may or may not contain other ginsenosides.
- the content of the ginsenoside Rg6 and ginsenoside F4 is preferably 50 parts by weight or more, more preferably 60 parts by weight or more, more preferably 70 parts by weight or more, more preferably 80 parts by weight or more, more preferably 90 parts by weight or more, more preferably 95 parts by weight or more, more preferably 99 parts by weight or more, more preferably 100 parts by weight (That is, the pharmaceutical composition only contains the above two ginsenosides), based on 100 parts by weight of the total ginsenosides contained in the pharmaceutical composition.
- the purity of ginsenoside Rg6 used in the pharmaceutical composition of the present invention may be more than 98%, and the purity of ginsenoside F4 may be more than 98%.
- the present invention also provides the use of the pharmaceutical composition of the present invention in the preparation of sleep-improving drugs.
- tablets When preparing solid preparations for oral administration, after adding excipients and optional binders, disintegrating agents, lubricants, coloring agents, flavoring agents, etc. to the main drug, tablets can be prepared according to conventional methods. , Coated tablets, granules, fine granules, powders, capsules, etc.
- pH regulators, buffers, suspending aids, solubilizers, stabilizers, isotonic agents, preservatives, etc. can be added to the main drug as needed, and then made into intravenous, subcutaneous, and intramuscular injections according to conventional methods .
- a freeze-dried product can also be prepared by a conventional method.
- suspending aid examples include methyl cellulose, Tween 80, hydroxyethyl cellulose, gum arabic, tragacanth powder, sodium carboxymethyl cellulose, polyoxyethylene sorbitol monolaurate, and the like.
- solubilizer examples include polyoxyethylene hydrogenated castor oil, Tween 80, nicotinamide, polyoxyethylene sorbitol monolaurate, polyethylene glycol, and castor oil fatty acid ethyl ester.
- Oral toxicity test two mutagenic tests, mouse bone marrow polychromatic erythrocyte count micronucleus test, sperm abnormality test, 30-day feeding safety evaluation test, and pathological tissue examination were carried out on the products of Examples 1-3.
- the test data did not find that the tested sample had obvious toxic effects. According to the acute toxicity classification standard, the tested sample was classified as non-toxic.
- the experimental group is set to 150mg/kg BW according to 10 times the daily intake of adults, and the rats in the negative control group and the model group are given normal saline daily.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
组别 | 剂量(mg/kg BW) | 试验动物数(只) | 入睡动物数(只) | 入睡时间(min) |
空白 | - | 10 | 0 | 0 |
阳性药 | 2.5 | 10 | 0 | 0 |
组合物1 | 150 | 10 | 0 | 0 |
组合物2 | 150 | 10 | 0 | 0 |
组合物3 | 150 | 10 | 0 | 0 |
人参皂苷Rg6 | 150 | 10 | 0 | 0 |
人参皂苷F4 | 150 | 10 | 0 | 0 |
人参皂苷Rg1 | 150 | 10 | 0 | 0 |
人参皂苷Rb1 | 150 | 10 | 0 | 0 |
组别 | 剂量(mg/kg BW) | 入睡动物(只) | 睡眠发生率(%) | CI值 |
空白 | - | 2 | 20 | - |
阳性药 | 0.25 | 5 | 50 * | - |
组合物1 | 150 | 6 | 60 * | 0.89 |
组合物2 | 150 | 4 | 40 | 1.33 |
组合物3 | 150 | 5 | 50* | 1.11 |
人参皂苷Rg6 | 150 | 4 | 40 | - |
人参皂苷F4 | 150 | 4 | 40 | - |
人参皂苷Rg1 | 150 | 4 | 40 | - |
人参皂苷Rb1 | 150 | 3 | 30 | - |
组别 | 样本数 | 5-HT(ng/g) | GABA(ng/g) | Glu(pg/g) | Glu/GABA |
空白 | 6 | 316±8.34 | 7.04±0.44 | 81.39±2.46 | 0.011±0.001 |
模型组 | 6 | 246±7.26 △ | 4.49±0.37 △ | 119.59±2.03 △ | 0.027±0.002 △ |
Rg6组 | 6 | 286±7.59 * | 4.20±0.22 △ | 115.36±1.61 △ | 0.027±0.001 △ |
F4组 | 6 | 259±10.27 △ | 5.92±0.41 * | 97.99±2.26 * | 0.017±0.001 * |
组合物组 | 6 | 315±6.48 ** | 6.96±0.07 * | 89.30±2.03 * | 0.013±0.0003 ** |
Claims (10)
- 一种用于改善睡眠的药物组合物,其包含作为活性成分的改善睡眠有效量的人参皂苷Rg6和人参皂苷F4、以及药学可接受的载体,该药物组合物中,所述人参皂苷Rg6和人参皂苷F4的重量比为1∶1~3∶1。
- 根据权利要求1所述的药物组合物,所述药物组合物中,所述人参皂苷Rg6和人参皂苷F4的重量比为2∶1。
- 根据权利要求1所述的药物组合物,以所述药物组合物中包含的总人参皂苷为100重量份计,所述药物组合物中包含的人参皂苷Rg6和人参皂苷F4合计为10重量份以上,优选50重量份以上。
- 根据权利要求1所述的药物组合物,以所述药物组合物中包含的总人参皂苷为100重量份计,所述药物组合物中包含的人参皂苷Rg6和人参皂苷F4合计为100重量份。
- 根据权利要求1所述的用途,其中,所述药物组合物不包含除人参皂苷Rg6和人参皂苷F4之外的其它改善睡眠的有效成分。
- 人参皂苷Rg6和人参皂苷F4在制备用于改善睡眠的药物组合物中的用途,其中,该药物组合物中,所述人参皂苷Rg6和人参皂苷F4的重量比为1∶1~3∶1。
- 根据权利要求6所述的用途,其中,所述药物组合物中,所述人参皂苷Rg6和人参皂苷F4的重量比为2∶1。
- 根据权利要求6所述的用途,其中,以所述药物组合物中包含的总人参皂苷为100重量份计,所述药物组合物中包含的人参皂苷Rg6和人参皂苷F4合计为10重量份以上,优选50重量份以上。
- 根据权利要求6所述的用途,以所述药物组合物中包含的总人参皂苷为100重量份计,所述药物组合物中包含的人参皂苷Rg6和人参皂苷F4合计为100重量份。
- 根据权利要求6所述的用途,其中,所述药物组合物不包含除人参皂苷Rg6和人参皂苷F4之外的其它改善睡眠的有效成分。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021260664A AU2021260664B2 (en) | 2020-04-24 | 2021-04-23 | Sleep-improving pharmaceutical composition containing rare ginsenosides Rg6 and F4 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010332902.0A CN111358803B (zh) | 2020-04-24 | 2020-04-24 | 包含稀有人参皂苷Rg6和F4的改善睡眠药物组合物 |
CN202010332902.0 | 2020-04-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021213502A1 true WO2021213502A1 (zh) | 2021-10-28 |
Family
ID=71199885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/089324 WO2021213502A1 (zh) | 2020-04-24 | 2021-04-23 | 包含稀有人参皂苷Rg6和F4的改善睡眠药物组合物 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN111358803B (zh) |
AU (1) | AU2021260664B2 (zh) |
WO (1) | WO2021213502A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111358803B (zh) * | 2020-04-24 | 2021-05-07 | 陕西巨子生物技术有限公司 | 包含稀有人参皂苷Rg6和F4的改善睡眠药物组合物 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120081758A (ko) * | 2011-01-12 | 2012-07-20 | 충남대학교산학협력단 | 진세노사이드의 면역성 질환의 예방 및 치료 용도 |
KR20130001875A (ko) * | 2011-06-28 | 2013-01-07 | 주식회사 락토스 | 목초액을 이용한 희소 진세노사이드의 제조 |
CN103271891A (zh) * | 2013-04-28 | 2013-09-04 | 福建南方制药股份有限公司 | 人参皂苷纳米胶束及其制备方法、应用和药物组合物 |
CN104644655A (zh) * | 2013-11-20 | 2015-05-27 | 富力 | 20(R)-人参皂苷Rg3在制备缓解或/和治疗失眠症药物中的应用及药物 |
KR101718355B1 (ko) * | 2015-10-30 | 2017-03-21 | 충남대학교산학협력단 | 진세노사이드 Rg6, Rg4, Rh4 및 Rk3를 유효성분으로 포함하는 고혈압 또는 당뇨병성 족부궤양의 예방 또는 치료용 조성물 |
CN107141332A (zh) * | 2017-07-17 | 2017-09-08 | 南京普氟生物检测技术有限公司 | 一种高效、快速制备分离三种人参皂苷异构体Rg6、Z型和E型F4的方法 |
CN111358803A (zh) * | 2020-04-24 | 2020-07-03 | 陕西巨子生物技术有限公司 | 包含稀有人参皂苷Rg6和F4的改善睡眠药物组合物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1330357C (zh) * | 2004-06-03 | 2007-08-08 | 昆明香格喜玛生物技术有限责任公司 | 具有生理活性的复方人参二醇皂苷及其制剂及用途 |
-
2020
- 2020-04-24 CN CN202010332902.0A patent/CN111358803B/zh active Active
-
2021
- 2021-04-23 AU AU2021260664A patent/AU2021260664B2/en active Active
- 2021-04-23 WO PCT/CN2021/089324 patent/WO2021213502A1/zh active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120081758A (ko) * | 2011-01-12 | 2012-07-20 | 충남대학교산학협력단 | 진세노사이드의 면역성 질환의 예방 및 치료 용도 |
KR20130001875A (ko) * | 2011-06-28 | 2013-01-07 | 주식회사 락토스 | 목초액을 이용한 희소 진세노사이드의 제조 |
CN103271891A (zh) * | 2013-04-28 | 2013-09-04 | 福建南方制药股份有限公司 | 人参皂苷纳米胶束及其制备方法、应用和药物组合物 |
CN104644655A (zh) * | 2013-11-20 | 2015-05-27 | 富力 | 20(R)-人参皂苷Rg3在制备缓解或/和治疗失眠症药物中的应用及药物 |
KR101718355B1 (ko) * | 2015-10-30 | 2017-03-21 | 충남대학교산학협력단 | 진세노사이드 Rg6, Rg4, Rh4 및 Rk3를 유효성분으로 포함하는 고혈압 또는 당뇨병성 족부궤양의 예방 또는 치료용 조성물 |
CN107141332A (zh) * | 2017-07-17 | 2017-09-08 | 南京普氟生物检测技术有限公司 | 一种高效、快速制备分离三种人参皂苷异构体Rg6、Z型和E型F4的方法 |
CN111358803A (zh) * | 2020-04-24 | 2020-07-03 | 陕西巨子生物技术有限公司 | 包含稀有人参皂苷Rg6和F4的改善睡眠药物组合物 |
Non-Patent Citations (1)
Title |
---|
SHAO JINGJING, ZHENG XIAOYAN, QU LINLIN, ZHANG HUI, YUAN HUIFANG, HUI JUNFENG, MI YU, MA PEI, FAN DAIDI: "Ginsenoside Rg5/Rk1 ameliorated sleep via regulating the GABAergic/serotoninergic signaling pathway in a rodent model", FOOD & FUNCTION, vol. 11, no. 2, 3 February 2020 (2020-02-03), XP055860627, DOI: 10.1039/C9FO02248A * |
Also Published As
Publication number | Publication date |
---|---|
CN111358803A (zh) | 2020-07-03 |
AU2021260664A1 (en) | 2023-01-05 |
CN111358803B (zh) | 2021-05-07 |
AU2021260664B2 (en) | 2024-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3513796A1 (en) | Sleep disorder improvement agent and method for improving sleep disorders | |
EP2644198B1 (en) | Antianxiety and sleep disorder improving use of albiflorin | |
WO2021197372A1 (zh) | 包含稀有人参皂苷Rk2、CK和PPT的抗肿瘤组合物 | |
WO2019114428A1 (zh) | 一种具有改善睡眠和/或抗抑郁功效的保健组合物和保健食品 | |
DE60034373T2 (de) | Methode und zusammensetzung zur behandlung von resistenz gegen antihypertensiva und verwandten zuständen | |
AU2023202003A1 (en) | Melatonin mini-tablets and method of manufacturing the same | |
WO2021213502A1 (zh) | 包含稀有人参皂苷Rg6和F4的改善睡眠药物组合物 | |
US20230125425A1 (en) | Traditional chinese medicine extract composition with function of regulating depressive emotion and preparation method and traditional chinese medicine preparation thereof | |
WO2023080409A1 (ko) | 산조인 분말 및 영실 분말을 포함하는 수면 장애의 예방 또는 개선용 조성물 | |
JP2004091473A (ja) | 色素沈着改善治療薬 | |
CN110269897B (zh) | 一种抗疲劳和改善睡眠的组合物及其用途 | |
CN107595850A (zh) | 一种有效提高睡眠质量的药物组合物及其用途 | |
CN111000862A (zh) | 靶向线粒体逆转早早期癌症的药物组合物及其应用 | |
CN112641788A (zh) | 5-甲基四氢叶酸组合物用于改善睡眠的应用 | |
EP3375439A1 (en) | Composition for alleviating, preventing or treating premenstrual syndrome, containing, as active ingredient, pinitol, d-chiro-inositol or analog compound thereof | |
CN111973681B (zh) | 一种戒断治疗阿普唑仑依赖型焦虑性失眠的药物 | |
CN107496516B (zh) | 一种治疗失眠的组合物及其制备方法 | |
WO2024134475A1 (en) | Medicinal formulation from withania somnifera extract for treating sleep disorders and the preparation thereof | |
CN105709228A (zh) | 一种用于保护心肌缺血的药物组合物及其制备方法 | |
CN116327788A (zh) | 一种治疗失眠的皂苷组合物 | |
CN107582554A (zh) | 一种抗失眠药物组合物及其用途 | |
CN116036232A (zh) | 一种含5-氨基乙酰丙酸或其衍生物的安神助眠药剂及制备方法和应用 | |
CN107812007A (zh) | 一种治疗失眠的药物组合物及其用途 | |
CN103919989B (zh) | 一种治疗癫狂性精神分裂症的口服中药制剂及其制备方法 | |
Mendels | Thioproperazine-induced lactation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21792593 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021260664 Country of ref document: AU Date of ref document: 20210423 Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21792593 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21792593 Country of ref document: EP Kind code of ref document: A1 |